Eton Pharmaceuticals, Inc. 8-K

What Happened
Eton Pharmaceuticals announced on an 8-K that on February 27, 2026 it entered into a licensing agreement to acquire U.S. rights to HEMANGEOL® (propranolol) oral solution from Pierre Fabre Medicament Sas. HEMANGEOL is an FDA‑approved orphan drug for proliferating infantile hemangioma requiring systemic therapy. Eton will pay $14.0 million upfront, fund inventory purchases, and will assume commercialization in the U.S. after a transition distribution period ending April 30, 2026. The company said the deal was financed with cash on hand and is expected to be accretive to 2026 earnings.

Key Details

• Licensing agreement signed February 27, 2026; press release attached as Exhibit 99.1 (dated March 2, 2026).
• Upfront payment: $14.0 million; ongoing obligation: 8% royalty on net sales for the product’s patent-protected life.
• Inventory purchases: approx. $1.5 million at closing and an estimated $0.7 million in May 2026.
• Transition services: Licensor will distribute HEMANGEOL in the U.S. through April 30, 2026; Eton will commercialize thereafter.
• Market context: IQVIA reports 2025 U.S. sales of HEMANGEOL were $11.7 million.

Why It Matters
This is an acquisition of a marketed specialty product that adds an immediate revenue stream and a commercial product to Eton’s portfolio. The upfront cost and inventory purchases were funded with existing cash, and Eton expects the deal to be accretive to 2026 earnings—important for investors watching near-term profitability. The 8% royalty and inventory costs will affect margins on sales, and the April 30 transition end date sets the timeline for when Eton will begin full U.S. commercialization.